[
  {
    "ts": null,
    "headline": "Denali Therapeutics: Navigating Through Recent Setbacks",
    "summary": "Denali Therapeutics: Navigating Through Recent Setbacks",
    "url": "https://finnhub.io/api/news?id=f5cab6aadc4cc476ee8796607671730907ad5e7bb681e1cfd33176010cb1b7d4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750948566,
      "headline": "Denali Therapeutics: Navigating Through Recent Setbacks",
      "id": 135561460,
      "image": "",
      "related": "BIIB",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=f5cab6aadc4cc476ee8796607671730907ad5e7bb681e1cfd33176010cb1b7d4"
    }
  },
  {
    "ts": null,
    "headline": "5 Revealing Analyst Questions From Biogen’s Q1 Earnings Call",
    "summary": "Biogen’s first quarter results outpaced Wall Street’s expectations, prompting a positive market reaction. Management highlighted the expanding contribution from its newer neurology and rare disease products, such as LEQEMBI, SKYCLARYS, and ZURZUVAE, which now comprise nearly half of product revenue. CEO Chris Viehbacher described this as evidence of a “new Biogen” emerging, with these products gaining commercial traction and benefiting from expanded approvals, particularly in Europe and Brazil.",
    "url": "https://finnhub.io/api/news?id=91cfff372e8aa4a887791999919b3430d59aacec39f289b1840fba9db369024a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750924009,
      "headline": "5 Revealing Analyst Questions From Biogen’s Q1 Earnings Call",
      "id": 135558965,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen’s first quarter results outpaced Wall Street’s expectations, prompting a positive market reaction. Management highlighted the expanding contribution from its newer neurology and rare disease products, such as LEQEMBI, SKYCLARYS, and ZURZUVAE, which now comprise nearly half of product revenue. CEO Chris Viehbacher described this as evidence of a “new Biogen” emerging, with these products gaining commercial traction and benefiting from expanded approvals, particularly in Europe and Brazil.",
      "url": "https://finnhub.io/api/news?id=91cfff372e8aa4a887791999919b3430d59aacec39f289b1840fba9db369024a"
    }
  }
]